Journey Medical Q2 Revenue Up 23% to $18.5M, Loss Narrows to $0.3M
DERM sits 53% above its 52-week low of $4.31.
Summary
Journey Medical reported Q2 2026 revenue of $18.5 million, up 23% year-over-year, with Emrosi sales reaching $8.1 million. Net loss narrowed to $0.3 million from $3.8 million, and the company achieved positive Adjusted EBITDA.
Key Events · Earnings and Guidance · DERM
-
Q2 Revenue Up 23%
Total revenue reached $18.5 million, up from $15.0 million in Q2 2025, driven by Emrosi sales of $8.1 million.
-
Net Loss Narrows Sharply
GAAP net loss improved to $0.3 million ($0.01 per share) from $3.8 million ($0.16 per share) in the prior-year quarter.
-
Positive Adjusted EBITDA
Non-GAAP Adjusted EBITDA was $2.9 million for Q2 2026, compared to negative $0.5 million in Q2 2025.
-
Emrosi Prescriptions Growing
Total prescriptions for Emrosi reached approximately 36,000 in Q2 2026, up from 30,000 in Q1 2026 and 27,000 in Q4 2025.
Analysis · DERM · Life Sciences
A strong second quarter for Journey Medical was driven by 23% revenue growth from Emrosi, its rosacea treatment. The net loss narrowed dramatically from $3.8 million to just $0.3 million, and the company achieved positive non-GAAP Adjusted EBITDA of $2.9 million. With $25.6 million in cash and growing prescription demand, profitability is approaching, though a going concern warning remains in its filings.
At the time of this filing, DERM was trading at $6.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $177M. The 52-week trading range was $4.31 to $9.56. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.